伊马替尼对儿童急性淋巴细胞白血病的疗效

Efficacy of imatinib in the treatment of children with acute lymphoblastic leukemia

目的观察伊马替尼对BCR-ABL融合基因阳性儿童急性淋巴细胞白血病(ALL)的疗效。方法回顾性分析10例BCR-ABL P-190融合基因阳性ALL患儿的临床特点及治疗。结果 10例患儿中,平均发病年龄(9.60±2.97)岁,均为B-细胞性ALL,7例(70%)治疗第19天骨髓完全缓解,9例(90%)治疗第35天骨髓完全缓解,9例(90%)患儿体内微小残留病变持续转阴,7例(70%)BCR-ABL P190融合基因持续阴性,2例(20%)BCR-ABL P190融合基因持续阳性。结论对BCR-ABL融合基因阳性的ALL患儿,在化疗的基础上及早加用伊马替尼可明显提高缓解率。

Objective To observe the curative effect of imatinib on BCR-ABL fusion gene positive children with acute lymphoblastic leukemia （ALL）. Methods The clinical features and treatment of 10 cases of BCR-ABLP190 fusion gene positive ALL in children were retrospectively analyzed. Results In 10 cases, the average age of onset was （9.60±2.97） years old ; all of which were B- cell ALL. 7 cases （70%） were treated for nineteenth day with complete remission of bone marrow; 9 cases （90%）the bone marrow was completely relieved in thirty-fifth day; 9 cases （90%） of the minimal residual disease （ MRD ） were negative continuously ; 7 cases （ 70% ） of BCR-ABLP190 fusion genes were negative continuously ; 2 cases （20%） of BCR-ABLP190 fusion gene was negative continuously. Conclusion For BCR-ABL fusion gene positive ALL children, on the basis of chemotherapy, use of imatinib at early stage could improve the remission rate significantly.